CSTONE PHARMA-B (02616) opened nearly 5% higher during the morning trading session. At the time of reporting, the stock was up 4.99%, trading at HK$10.3 with a turnover of HK$3.2136 million.

On April 22, CSTONE PHARMA-B announced that multiple key clinical advancements for its internally developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, will be formally presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting through two poster presentations. The disclosed content will include Phase I/II clinical trial data for CS2009 in non-small cell lung cancer (NSCLC) cohorts (first-line and later-line), as well as extended follow-up results from the Phase I clinical trial involving patients with advanced solid tumors.

The announcement stated that the global multi-center Phase I/II clinical trial for CS2009 is progressing rapidly, with concurrent efforts in Australia and China. An Investigational New Drug (IND) application has also been approved in the United States. The company is actively preparing to initiate the first Phase III international multi-center clinical trial (MRCT) before the end of the year, focusing on indications such as NSCLC and colorectal cancer (CRC). To date, over 200 subjects have been enrolled. CS2009 has demonstrated excellent safety and tolerability across all evaluated dose groups, with no occurrence of the severe toxicities commonly associated with combination therapies containing CTLA-4 and PD-(L)1 inhibitors. This establishes a solid clinical safety foundation for potential combination use with chemotherapy or antibody-drug conjugates (ADCs).